YUM! Brands, Inc. (YUM) Forms $82.43 Double Top; Vaxart (VXRT) Shorts Lowered By 61.75%

YUM! Brands, Inc. (NYSE:YUM) Logo

YUM! Brands, Inc. (YUM) formed double top with $89.85 target or 9.00% above today’s $82.43 share price. YUM! Brands, Inc. (YUM) has $27.07B valuation. The stock decreased 0.29% or $0.24 during the last trading session, reaching $82.43. About 2.14 million shares traded. YUM! Brands, Inc. (NYSE:YUM) has risen 32.07% since May 5, 2017 and is uptrending. It has outperformed by 20.52% the S&P500.

Vaxart Inc (NASDAQ:VXRT) had a decrease of 61.75% in short interest. VXRT’s SI was 15,300 shares in May as released by FINRA. Its down 61.75% from 40,000 shares previously. With 24,000 avg volume, 1 days are for Vaxart Inc (NASDAQ:VXRT)’s short sellers to cover VXRT’s short positions. The stock increased 5.41% or $0.28 during the last trading session, reaching $5.46. About 190,231 shares traded or 144.81% up from the average. Vaxart, Inc. (NASDAQ:VXRT) has declined 25.31% since May 5, 2017 and is downtrending. It has underperformed by 36.86% the S&P500.

More recent Vaxart, Inc. (NASDAQ:VXRT) news were published by: Streetinsider.com which released: “Vaxart, Inc. (VXRT) Reports $5M Inavir Revenue Milestone Payment from Daiichi Sankyo Co. for Exceeding Sales …” on April 20, 2018. Also Businesswire.com published the news titled: “Vaxart to Present at Two Upcoming Medical Meetings” on April 16, 2018. Businesswire.com‘s news article titled: “Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations” with publication date: April 19, 2018 was also an interesting one.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company has market cap of $38.98 million. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus vaccines, as well as other recombinant vaccines. It currently has negative earnings. The Company’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.01, from 0.99 in 2017Q3. It worsened, as 48 investors sold YUM! Brands, Inc. shares while 251 reduced holdings. 88 funds opened positions while 205 raised stakes. 235.88 million shares or 1.51% less from 239.50 million shares in 2017Q3 were reported. 33,633 are owned by Conning. Godshalk Welsh Cap Mgmt holds 0.58% or 6,975 shares. Everence Mgmt invested in 8,071 shares. Needelman Asset Mngmt Inc reported 2.31% stake. Wellington Shields Capital Limited Liability Com accumulated 9,600 shares. Freshford Cap Management Lc, New York-based fund reported 228,722 shares. 85,021 were accumulated by Com State Bank. Omers Administration Corp has 0.06% invested in YUM! Brands, Inc. (NYSE:YUM). Windsor Capital Mngmt Limited Liability Corporation has invested 0.4% in YUM! Brands, Inc. (NYSE:YUM). Todd Asset Management Lc invested in 196,854 shares. Fmr Lc reported 0.02% in YUM! Brands, Inc. (NYSE:YUM). Catalyst Cap Advsr Ltd Liability Com reported 3,900 shares stake. Moreover, Evercore Wealth Management Limited Liability has 0.01% invested in YUM! Brands, Inc. (NYSE:YUM). Old Natl National Bank In has 8,888 shares. Salem Investment Counselors holds 0.18% or 20,556 shares.

Among 29 analysts covering YUM! Brands (NYSE:YUM), 12 have Buy rating, 1 Sell and 16 Hold. Therefore 41% are positive. YUM! Brands has $116 highest and $45.1 lowest target. $84.87’s average target is 2.96% above currents $82.43 stock price. YUM! Brands had 109 analyst reports since July 1, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 3 by Oppenheimer. Oppenheimer maintained YUM! Brands, Inc. (NYSE:YUM) rating on Wednesday, May 2. Oppenheimer has “Buy” rating and $9000 target. Barclays Capital maintained YUM! Brands, Inc. (NYSE:YUM) on Thursday, May 3 with “Equal-Weight” rating. As per Wednesday, April 26, the company rating was maintained by Cowen & Co. Credit Suisse maintained the stock with “Neutral” rating in Monday, March 28 report. Morgan Stanley maintained it with “Equal-Weight” rating and $96 target in Wednesday, September 28 report. The stock of YUM! Brands, Inc. (NYSE:YUM) has “Buy” rating given on Wednesday, April 18 by Cowen & Co. Stifel Nicolaus maintained YUM! Brands, Inc. (NYSE:YUM) rating on Wednesday, May 2. Stifel Nicolaus has “Buy” rating and $9400 target. The stock of YUM! Brands, Inc. (NYSE:YUM) earned “Buy” rating by Argus Research on Tuesday, May 16. As per Friday, November 13, the company rating was maintained by Oppenheimer.

YUM! Brands, Inc. (NYSE:YUM) Institutional Positions Chart